Key features and details
- Mouse monoclonal [VWF/1465] to Von Willebrand Factor
- Suitable for: WB, IHC-P
- Reacts with: Human
- Isotype: IgG1
Product nameAnti-Von Willebrand Factor antibody [VWF/1465]
See all Von Willebrand Factor primary antibodies
DescriptionMouse monoclonal [VWF/1465] to Von Willebrand Factor
Tested applicationsSuitable for: WB, IHC-Pmore details
Species reactivityReacts with: Human
Recombinant fragment within Human Von Willebrand Factor aa 1815-1939. The exact sequence is proprietary.
ARSNRV TVFPIGIGDR YDAAQLRILA GPAGDSNVVK LQRIEDLPTM VTLGNSFLHK LCSGFVRICM DEDGNEKRPG DVWTLPDQCH TVTCQPDGQT LLKSHRVNCD RGLRPSCPNS QSPVKVEET
Database link: P04275
- Human lung lysate; Human tonsil tissue.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.05% Sodium azide
Constituents: 99% PBS, 0.05% BSA
Concentration information loading...
PurityProtein A/G purified
Our Abpromise guarantee covers the use of ab218333 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 0.5 - 1 µg/ml. Predicted molecular weight: 309 kDa.|
|IHC-P||Use a concentration of 1 - 2 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionImportant in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
Involvement in diseaseDefects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
Sequence similaritiesContains 1 CTCK (C-terminal cystine knot-like) domain.
Contains 4 TIL (trypsin inhibitory-like) domains.
Contains 3 VWFA domains.
Contains 3 VWFC domains.
Contains 4 VWFD domains.
DomainThe von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
modificationsAll cysteine residues are involved in intrachain or interchain disulfide bonds.
N- and O-glycosylated.
Cellular localizationSecreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.
- Information by UniProt
- Coagulation factor VIII antibody
- Coagulation factor VIII VWF antibody
- F8VWF antibody
All lanes : Anti-Von Willebrand Factor antibody [VWF/1465] (ab218333) at 1 µg/ml
Lane 1 : Recombinant protein
Lane 2 : Human lung lysate
Predicted band size: 309 kDa
Immunohistochemical analysis of Formalin-fixed, paraffin-embedded Human tonsil tissue labeling Von Willebrand Factor with ab218333 at 2µg/ml.
ab218333 has not yet been referenced specifically in any publications.